James Thorne

James Thorne

Quantivate raises undisclosed investment from Luminate Capital Partners; three Luminate partners join board

Quantivate, a Woodinville startup selling risk management and regulatory compliance software for regulated industries, raised an undisclosed funding round led solely by Luminate Capital Partners, which is placing three partners on Quantivate’s board. The company plans to use the partnership to accelerate product innovation, scale its team, and expand customer value in the growing GRC market.

Twistle raises $16M Series A from Health Enterprise Partners and MemorialCare to automate hospital–patient communication

Twistle raised $16 million in a Series A led by Health Enterprise Partners and MemorialCare Innovation Fund to expand its platform that automates patient communication, education, and data collection for health systems. The company will use the funding to grow sales and invest in human-assisted automation as it competes with startups like Klara and Voalte and larger tech entrants such as Microsoft.

Cadence Neuroscience raises $15M Series A led by Jazz to develop Mayo Clinic–based implantable epilepsy device

Cadence Neuroscience raised $15 million in a Series A led by Jazz Venture Partners, plus support from Mayo Clinic and Epilepsy Foundation grants, to develop an implantable epilepsy therapy based on Mayo Clinic research. The Redmond startup hopes to leverage existing clinical data to accelerate development of a device aimed at patients whose seizures are not controlled by drugs.

Outreach’s Manny Medina, Auth0’s Eugenio Pace, and Convoy’s Dan Lewis Share Team-Building, Mission, and Scaling Advice

At the GeekWire Summit, CEOs Manny Medina (Outreach), Eugenio Pace (Auth0), and Dan Lewis (Convoy) shared practical advice on building teams, defining meaningful missions, company values, and scaling sustainably. They emphasized attracting talent with a resonant mission, leading boldly into challenges, and growing without sacrificing core principles.

Fred Hutch spinout SEngine Precision Medicine raises $5.1M Series A to commercialize PARIS tumor‑testing platform

SEngine Precision Medicine raised $5.1 million to commercialize its PARIS platform, which grows patients’ tumor cells in the lab to test safety and effectiveness of over 200 drugs or drug combinations and help match cancer patients to therapies. The company also gathers data for drug discovery, has a joint venture with Atomwise, and completed a Series A led by the Bangarang Group.

Axon hires ex-Amazon exec Jeff Kunins as Chief Product Officer; PayScale sees latest C-suite exit

Axon hired former Amazon executive Jeff Kunins as chief product officer and executive vice president of software, who will be based in Seattle; PayScale lost another senior executive as chief product and strategy officer Dave Smith departed amid several recent leadership exits. Startups Armoire and others added leaders too, with Armoire naming Berea Schaffer as head of product and technology after a $3.9 million seed round.

UW Spinout Split Bio Raises $560,000 Bridge Round to Scale Whole Transcriptome Single‑Cell RNA‑Seq Kits, Total Funding Reaches $2M

University of Washington spinout Split Bio raised $560,000 in bridge financing to scale production of its Whole Transcriptome single-cell RNA sequencing kits, bringing total funding to $2 million. The startup—founded by Georg Seelig lab researchers Alex Rosenberg and Charles Roco—sells SPLiT-seq kits that don’t require custom instruments and aim to offer scalable, flexible sample processing.

Vector Capital buys meaningful stake in Windermere spinout MoxiWorks to fund expansion

MoxiWorks, a Seattle startup spun out of Windermere Real Estate, has sold a “meaningful” undisclosed stake to private equity firm Vector Capital to fund product development, sales and marketing, and potential acquisitions. Its brokerage-focused SaaS is used by 80 brokerages representing 130,000 agents, and Vector — which manages $4 billion — called MoxiWorks well positioned to capture the growing real estate technology market.

LumiThera raises $1.15M to advance Valeda photobiomodulation device for dry AMD, in U.S. trials and EU‑approved

LumiThera raised $1.15 million to advance its Valeda Light Delivery System, a photobiomodulation device aimed at improving and slowing vision loss in patients with dry age-related macular degeneration that is in U.S. clinical trials and approved for sale in the EU. The Poulsbo, Washington startup, co‑founded and led by CEO Clark Tedford, lists investors including Keiretsu Forum Northwest and executives with medical-device experience on its leadership team.

Online